Editorial

Basic research in bladder cancer – refining the tools. 3rd IBCN seminars series1

Peter C. Black, Peter J. Goebell, Ashish M. Kamat, Roman Nawroth, Roland Seiler, Stephen Williams, Bernd J. Schmitz-Dräger

    Research output: Contribution to journalArticle

    Abstract

    This editorial highlights submissions to part II of the 3rd IBCN Seminars Series particularly focusing on the tools required for conduction of translational research in bladder cancer. One of the submissions describe the ex vivo culture of primary tumor cells from N-methyl-N-nitrosourea-induced bladder tumors in rats and subsequent establishment of an immortalized cell line. In a next step the authors thoroughly characterize this cell line. They conclude that differentiation marker expression patterns observed in the original tumors are largely retained in the spheroids. Although new cancer models, such as organoid tissue cultures, hold great promise for studying cancer progression and might have a potential for development and selection of an optimal treatment, their limitations must be kept in mind. The second submission, therefore, critically questions the current role of organoid tissue culture as a predictive tool in urothelial cancer patients. The third manuscript of this series provides a broader overview of post-translational modification in bladder cancer is presented and how PTMs can be exploited as potential therapeutic targets. The 3 manuscripts featured in this issue demonstrate especially how basic research is being channeled to inform clinically actionable discoveries.

    Original languageEnglish (US)
    JournalUrologic Oncology: Seminars and Original Investigations
    DOIs
    StateAccepted/In press - Jan 1 2019

    Fingerprint

    Urinary Bladder Neoplasms
    Organoids
    Research
    Manuscripts
    Neoplasms
    Methylnitrosourea
    Cell Line
    Translational Medical Research
    Primary Cell Culture
    Differentiation Antigens
    Post Translational Protein Processing
    Therapeutics

    Keywords

    • Basic research
    • Bladder cancer
    • International Bladder Cancer Network (IBCN)
    • Tumor models

    ASJC Scopus subject areas

    • Oncology
    • Urology

    Cite this

    Editorial : Basic research in bladder cancer – refining the tools. 3rd IBCN seminars series1. / Black, Peter C.; Goebell, Peter J.; Kamat, Ashish M.; Nawroth, Roman; Seiler, Roland; Williams, Stephen; Schmitz-Dräger, Bernd J.

    In: Urologic Oncology: Seminars and Original Investigations, 01.01.2019.

    Research output: Contribution to journalArticle

    Black, Peter C. ; Goebell, Peter J. ; Kamat, Ashish M. ; Nawroth, Roman ; Seiler, Roland ; Williams, Stephen ; Schmitz-Dräger, Bernd J. / Editorial : Basic research in bladder cancer – refining the tools. 3rd IBCN seminars series1. In: Urologic Oncology: Seminars and Original Investigations. 2019.
    @article{a47ccd0a409040ad88ae8b1874c0c764,
    title = "Editorial: Basic research in bladder cancer – refining the tools. 3rd IBCN seminars series1",
    abstract = "This editorial highlights submissions to part II of the 3rd IBCN Seminars Series particularly focusing on the tools required for conduction of translational research in bladder cancer. One of the submissions describe the ex vivo culture of primary tumor cells from N-methyl-N-nitrosourea-induced bladder tumors in rats and subsequent establishment of an immortalized cell line. In a next step the authors thoroughly characterize this cell line. They conclude that differentiation marker expression patterns observed in the original tumors are largely retained in the spheroids. Although new cancer models, such as organoid tissue cultures, hold great promise for studying cancer progression and might have a potential for development and selection of an optimal treatment, their limitations must be kept in mind. The second submission, therefore, critically questions the current role of organoid tissue culture as a predictive tool in urothelial cancer patients. The third manuscript of this series provides a broader overview of post-translational modification in bladder cancer is presented and how PTMs can be exploited as potential therapeutic targets. The 3 manuscripts featured in this issue demonstrate especially how basic research is being channeled to inform clinically actionable discoveries.",
    keywords = "Basic research, Bladder cancer, International Bladder Cancer Network (IBCN), Tumor models",
    author = "Black, {Peter C.} and Goebell, {Peter J.} and Kamat, {Ashish M.} and Roman Nawroth and Roland Seiler and Stephen Williams and Schmitz-Dr{\"a}ger, {Bernd J.}",
    year = "2019",
    month = "1",
    day = "1",
    doi = "10.1016/j.urolonc.2019.01.003",
    language = "English (US)",
    journal = "Urologic Oncology",
    issn = "1078-1439",
    publisher = "Elsevier Inc.",

    }

    TY - JOUR

    T1 - Editorial

    T2 - Basic research in bladder cancer – refining the tools. 3rd IBCN seminars series1

    AU - Black, Peter C.

    AU - Goebell, Peter J.

    AU - Kamat, Ashish M.

    AU - Nawroth, Roman

    AU - Seiler, Roland

    AU - Williams, Stephen

    AU - Schmitz-Dräger, Bernd J.

    PY - 2019/1/1

    Y1 - 2019/1/1

    N2 - This editorial highlights submissions to part II of the 3rd IBCN Seminars Series particularly focusing on the tools required for conduction of translational research in bladder cancer. One of the submissions describe the ex vivo culture of primary tumor cells from N-methyl-N-nitrosourea-induced bladder tumors in rats and subsequent establishment of an immortalized cell line. In a next step the authors thoroughly characterize this cell line. They conclude that differentiation marker expression patterns observed in the original tumors are largely retained in the spheroids. Although new cancer models, such as organoid tissue cultures, hold great promise for studying cancer progression and might have a potential for development and selection of an optimal treatment, their limitations must be kept in mind. The second submission, therefore, critically questions the current role of organoid tissue culture as a predictive tool in urothelial cancer patients. The third manuscript of this series provides a broader overview of post-translational modification in bladder cancer is presented and how PTMs can be exploited as potential therapeutic targets. The 3 manuscripts featured in this issue demonstrate especially how basic research is being channeled to inform clinically actionable discoveries.

    AB - This editorial highlights submissions to part II of the 3rd IBCN Seminars Series particularly focusing on the tools required for conduction of translational research in bladder cancer. One of the submissions describe the ex vivo culture of primary tumor cells from N-methyl-N-nitrosourea-induced bladder tumors in rats and subsequent establishment of an immortalized cell line. In a next step the authors thoroughly characterize this cell line. They conclude that differentiation marker expression patterns observed in the original tumors are largely retained in the spheroids. Although new cancer models, such as organoid tissue cultures, hold great promise for studying cancer progression and might have a potential for development and selection of an optimal treatment, their limitations must be kept in mind. The second submission, therefore, critically questions the current role of organoid tissue culture as a predictive tool in urothelial cancer patients. The third manuscript of this series provides a broader overview of post-translational modification in bladder cancer is presented and how PTMs can be exploited as potential therapeutic targets. The 3 manuscripts featured in this issue demonstrate especially how basic research is being channeled to inform clinically actionable discoveries.

    KW - Basic research

    KW - Bladder cancer

    KW - International Bladder Cancer Network (IBCN)

    KW - Tumor models

    UR - http://www.scopus.com/inward/record.url?scp=85060295666&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85060295666&partnerID=8YFLogxK

    U2 - 10.1016/j.urolonc.2019.01.003

    DO - 10.1016/j.urolonc.2019.01.003

    M3 - Article

    JO - Urologic Oncology

    JF - Urologic Oncology

    SN - 1078-1439

    ER -